SCH 900117

SCH 900117 is an investigational biologic drug, specifically a monoclonal antibody, developed by Schering-Plough (now Merck & Co.) for the treatment of rheumatoid arthritis. It functions by targeting and neutralizing interleukin-17A (IL-17A), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of autoimmune and inflammatory diseases. By binding to IL-17A, the drug prevents its interaction with the IL-17 receptor complex, thereby inhibiting the downstream inflammatory signaling pathways that contribute to joint destruction and pain in rheumatoid arthritis. SCH 900117 was evaluated in early-phase clinical trials, including rising single-dose and multiple-dose studies, to assess its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with rheumatoid arthritis. Following the merger of Schering-Plough and Merck & Co., development of this specific asset appears to have been discontinued.